Streetbeat News

Products Services

WKSP

Worksport is anticipating improved margins and cash preservation with upcoming product launches, including the high-demand AL4 cover and innovative clean-tech solutions.

Portfolio Pulse from Benzinga Newsdesk

October 17, 2024 | 11:30 am

WKSP

Worksport has announced a strategic plan to accelerate its path to profitability, projecting over $2 million in savings. This move is aimed at strengthening the company's financial stability ahead of upcoming product launches.

Portfolio Pulse from Benzinga Newsdesk

October 17, 2024 | 11:30 am

AA

EXPE

LCID

NFLX

TSMC

Wall Street is expected to open higher, driven by strong earnings from TSMC, which is boosting sentiment in tech stocks, particularly AI-related ones. Netflix's upcoming earnings report could influence the tech sector. Alcoa and TSMC saw significant premarket gains, while Lucid Group dropped sharply due to a stock offering. Oil prices rebounded, and gold hit a record high.

Portfolio Pulse from Shanthi Rexaline

October 17, 2024 | 11:24 am

PBM

Psyence Biomedical is confident in PsyLabs' progress towards producing GMP certified, nature-derived psychedelic APIs. After exporting psilocybin extract to the UK, PsyLabs is in phase two of development, focusing on upscaling purification for commercial viability and E.U. GMP certification.

Portfolio Pulse from Benzinga Newsdesk

October 17, 2024 | 11:21 am

NTRB

Nutriband has received approval from the Costa Rica Ministry of Health to produce and market its mosquito repellent patch. This development could expand Nutriband's market reach and potentially increase its revenue.

Portfolio Pulse from Benzinga Newsdesk

October 17, 2024 | 11:18 am

COTY

MGRX

XXII

The article highlights three oversold stocks in the consumer staples sector: Coty Inc, 22nd Century Group Inc, and Mangoceuticals. These stocks have RSI values indicating they are oversold, presenting potential buying opportunities. Coty Inc announced preliminary Q1 results and reiterated its FY25 outlook, while 22nd Century Group's CEO made a significant share purchase. Mangoceuticals announced a reverse stock split.

Portfolio Pulse from Avi Kapoor

October 17, 2024 | 11:18 am

MRNS

Marinus Pharmaceuticals presented new data from its Phase 3 RAISE trial of intravenous ganaxolone for refractory status epilepticus at the Neurocritical Care Society Annual Meeting.

Portfolio Pulse from Benzinga Newsdesk

October 17, 2024 | 11:09 am

ARAY

Accuray's CyberKnife System, used in the PACE-B trial, demonstrated that stereotactic body radiation therapy (SBRT) offers comparable cancer control and tolerability to conventional radiotherapy, while significantly reducing treatment time for prostate cancer patients.

Portfolio Pulse from Benzinga Newsdesk

October 17, 2024 | 11:08 am

SAGE

Sage Therapeutics is reorganizing its business operations to support the launch of Zurzuvae for postpartum depression and focus on pipeline development for Dalzanemdor in Huntington's disease. The reorganization includes a workforce reduction of about 33%, impacting over 165 employees, and is expected to be completed by the end of Q4 2024.

Portfolio Pulse from Benzinga Newsdesk

October 17, 2024 | 11:06 am

MRNS

Marinus Pharmaceuticals presented promising Phase 3 RAISE trial data at the Neurocritical Care Society Annual Meeting, showing that their IV Ganaxolone significantly reduced the median time to status epilepticus cessation to 4.2 minutes compared to 307.2 minutes for placebo.

Portfolio Pulse from Benzinga Newsdesk

October 17, 2024 | 11:06 am